GLP-1
If you've been following the GLP-1 weight loss space, you've likely heard of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). But a new drug is generating serious buzz among obesity researchers and clinicians: retatrutide, a triple hormone receptor agonist developed by Eli Lilly that targets GLP-1,
GLP-1
Two medications have transformed obesity treatment over the past few years: semaglutide (sold as Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). Both deliver remarkable results, but they work differently — and the evidence now clearly shows one outperforms the other on the
GLP-1
GLP-1
GLP-1
GLP-1
The semaglutide shortage is over and the rules have changed. Here's what patients and prescribers need to know about compounded semaglutide's legal status in 2026 under 503A and 503B.
GLP-1
GLP-1
Tirzepatide produces 22.5% mean weight loss at 15 mg — but only with correct titration and injection technique. This complete 2026 guide covers everything from the 2.5 mg initiation dose through the full schedule, autoinjector protocol, and side effect management.
GLP-1
Survodutide targets both the GLP-1 and glucagon receptors — and its Phase 3 SYNCHRONIZE readout, expected any day in 2026, could reframe how we think about obesity treatment and metabolic liver disease.
GLP-1
Wegovy HD (semaglutide 7.2 mg) launched in the U.S. this week after FDA approval in just 54 days. The STEP UP trial showed 20.7% mean weight loss — with 1 in 3 patients losing 25% or more of body weight.
GLP-1
Everything you need to know about semaglutide dosing in 2026 — from the first 0.25 mg dose through the full titration schedule, step-by-step injection technique, and practical strategies for managing side effects.
Peptides
A deep-dive into BPC-157: mechanisms of action, tissue healing research, subcutaneous and oral dosing protocols, the TB-500 stack, side effects, and 2026 regulatory status.